| LY2886721BACE inhibitor |
Sample solution is provided at 25 µL, 10mM.
Quality Control & MSDS
- View current batch:
- Purity = 98.95%
- COA (Certificate Of Analysis)
- HPLC
- NMR (Nuclear Magnetic Resonance)
- MSDS (Material Safety Data Sheet)
- Datasheet
Chemical structure
Related Biological Data
| Description | LY2886721 is an oral, small molecule inhibitor of β-site amyloid protein cleaving enzyme (BACE) used for the treatment of Alzheimer"s Disease. | |||||
| Targets | BACE | |||||
| IC50 | ||||||
| Animal experiment [1]: | |
Animal models | PDAPP mice |
Dosage form | 3, 10 or 30 mg/kg; p.o. |
Applications | At all 3 doses, LY2886721 significantly reduced hippocampal and cortical levels of Aβ1-x. In addition, LY2886721 significantly lowered brain parenchymal levels of C99 and sAPPβ. Although cortical levels of C99 were reduced significantly by LY2886721 at the doses of 10 and 30 mg/kg, the effect of LY2886721 at the dose of 3 mg/kg failed to reach statistical significance. On the other hand, the sAPPβ levels were significantly decreased by LY2886721 at all 3 doses. |
Other notes | Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. May PC, Willis BA, Lowe SL, Dean RA, Monk SA, Cocke PJ, Audia JE, Boggs LN, Borders AR, Brier RA, Calligaro DO, Day TA, Ereshefsky L, Erickson JA, Gevorkyan H, Gonzales CR, James DE, Jhee SS, Komjathy SF, Li L, Lindstrom TD, Mathes BM, Martényi F, Sheehan SM, Stout SL, Timm DE, Vaught GM, Watson BM, Winneroski LL, Yang Z, Mergott DJ. The potent BACE1 inhibitor LY2886721 elicits robust central Aβ pharmacodynamic responses in mice, dogs, and humans. J Neurosci. 2015 Jan 21;35(3):1199-210. | |
LY2886721 Dilution Calculator
calculate
LY2886721 Molarity Calculator
calculate
| Cas No. | 1262036-50-9 | SDF | Download SDF |
| Chemical Name | N-[3-[(4aS,7aS)-2-amino-4,4a,5,7-tetrahydrofuro[3,4-d][1,3]thiazin-7a-yl]-4-fluorophenyl]-5-fluoropyridine-2-carboxamide | ||
| Canonical SMILES | C1C2CSC(=NC2(CO1)C3=C(C=CC(=C3)NC(=O)C4=NC=C(C=C4)F)F)N | ||
| Formula | C18H16F2N4O2S | M.Wt | 390.41 |
| Solubility | ≥19.52mg/mL in DMSO | Storage | Store at -20°C |
| Physical Appearance | A solid | Shipping Condition | Evaluation sample solution : ship with blue ice.All other available size:ship with RT , or blue ice upon request |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. | ||
LY2886721 is an oral and furothiazine-based inhibitor of β site-amyloid protein cleaving enzyme (BACE) with IC50 of 20.3nM. This product has the potency for the treatment of Alzheimer"s disease.
BACE, also known as Beta-Secretase 1, is an aspartic-acid protease that plays important role in the formation of myelin sheaths in peripheral nerve cells.
In vitro, treatment of LY2886721 leads to the inhibition of Aβ in HEK293Swe with IC50 of 18.7nM and PDAPP neuronal culture with IC50 10.7 nM1. LY2886721 decreases CSF sAPPβ and increases CSF sAPPα in a dose- dependent manner 2.
In PDAPP mice, oral administration of LY2886721 resulted in a reduction in brain Aβ, C99 and sAPPβ in a dose-dependent pattern 2. Aβ levels in the brain were decreased by 20% -65% as compared with the vehicle-treated groups 3 hours after treatment of LY2886721 at a dosage of 3-30 mg/kg per mice. In addition, LY2886721 significantly lowers plasma and CSF Aβs in the MAD study 1.
References:1. Vassar R. BACE1 inhibitor drugs in clinical trials for Alzheimer"s disease. Alzheimer"s research & therapy. 2014;6(9):89.2. Nishitomi K, Sakaguchi G, Horikoshi Y, et al. BACE1 inhibition reduces endogenous Abeta and alters APP processing in wild-type mice. Journal of neurochemistry. 2006;99(6):1555-1563.
ebiomall.com
>
>
>
>
>
>
>
>
>
>
>
>
2.将构建完成的载体与慢病毒包装质粒混合,共转染靶细胞
3.收集病毒液
4.用病毒液感染靶细胞
5.用载体上带的抗生素进行筛选,如果没有,可以用无限稀释法
6.获得稳转株
原代细胞(primary cell) 是指从机体的组织(如人组织、小鼠组织、大鼠组织和兔组织等)经蛋白酶或其它的方法获得单个细胞并在体外进行模拟机体培养的细胞，称为原代细胞。一般认为，培养的原代的第1代细胞和传代到第10代以内的细胞统称为原代细胞培养。在人工条件下使其原代细胞生存、生长、繁殖和传代，进行细胞生命过程、细胞癌变、细胞工程等问题的研究。
细胞株(cell strain) 是通过选择法或克隆形成法从原代培养细胞中获得具有特殊性质或标志物的细胞称为细胞株。一般认为，细胞株是用单细胞分离培养或通过筛选的方法，由单细胞增殖形成的细胞群。细胞株的特殊性质或标志必须在整个培养期间始终存在。
细胞系(cell line) 是原代细胞经首次传代成功后即为细胞系。泛指一般可能传代的细胞。其中能够连续传代的细胞叫做连续细胞系或无限细胞系，不能连续培养的称为有限细胞系。大多数二倍体细胞为有限细胞系。由原先存在于原代培养物中的细胞世系所组成。如果不能继续传代，或传代次数有限， 可称为有限细胞系(finite cell line)， 如可以连续培养， 则称为连续细胞系(continuous cell line)， 培养50代以上并无限培养下去。人类肿瘤细胞，在体外培养半年以上，生长稳定，并连续传代的即可称为连续性株或系。
如题，本人在做结肠肿瘤细胞时，每次从医院拿回来的组织都只有一指甲盖大小，我是剔除肉眼可见的一些血丝之类的，然后就进行处理了，不知道这样对不对，有没有清除干净，不知道大家在做肿瘤原代时，是怎么判断那一部分是肿瘤组织，有什么建议么？大家可以分享自己的经验。
干细胞的分类：
一） 根据个体发育过程中出现的先后次序不同，干细胞又可分为胚胎干细胞和成体干细胞。
(1)胚胎干细胞，它是一种高度未分化细胞。它具有发育的全能性，能分化出成体动物的所有组织和器官，包括生殖细胞。
(2)成体干细胞，它是存在于成年动物的许多组织和器官，比如表皮和造血系统，具有修复和再生的能力的细胞。在特定条件下，成体干细胞或者产生新的干细胞，或者按一定的程序分化，形成新的功能细胞，从而使组织和器官保持生长和衰退的动态平衡。
二）按分化潜能的大小，干细胞还可分为全能性干细胞、 多能性干细胞、单能干细胞等三种类型：
(1)全能性干细胞，它具有形成完整个体的分化潜能。如胚胎干细胞(简称ES细胞)，具有与早期胚胎细胞相似的形态特征和很强的分化能力，可以无限增殖并分化成为全身200多种细胞类型，进一步形成机体的所有组织、器官。人类的全能干细胞可以分化成人体的各种细胞，这些分化出的细胞构成人体的各种组织和器官，最终发育成一个完整的人。人类的精子和卵子结合后形成受精卵，这个受精卵就是一个最初始的全能干细胞。
(2)多能性干细胞，这种干细胞具有分化出多种细胞组织的潜能，但却失去了发育成完整个体的能力，发育潜能受到一定的限制，骨髓多能造血干细胞是典型的例子，它可分化出至少十二种血细胞，但不能分化出造血系统以外的其它细胞。
(3)单能干细胞(也称专能、偏能干细胞)，这类干细胞只能向一种类型或密切相关的两种类型的细胞分化，如上皮组织基底层的干细胞、肌肉中的成肌细胞或叫卫星细胞。
关于第一问能回答的详细点么？谢谢各位大虾~~
